Cell News and Research

RSS

PAF receives additional funding support for serving patients with multiple myeloma

Patient Advocate Foundation (PAF) -- a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases -- is pleased to announce that it has received additional funding support for serving patients with multiple myeloma through its Co-Pay Relief Program (CPR).

13 Nov 2009

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Pharmacyclics, Inc. today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.

13 Nov 2009

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses.

13 Nov 2009

Findings on the use of Traumeel S in children with mucositis undergoing SCT presented

New research findings presented today at the Society for Integrative Oncology's (SIO) Sixth International Conference in New York show promise in assessing the efficacy and safety of complementary and alternative medicine (CAM) using traditional research methods.

13 Nov 2009

New knowledge of basic science may be applied in future medical treatments

How does the developing pancreas in an embryo 'know' which cells are to produce insulin and which cells are to have other assignments? Researchers need to understand this if they want to be able to treat type-1 diabetes with stem cells developed into insulin-producing beta cells. At Lund University scientists have uncovered pioneering new knowledge, and are publishing it in the journal Cell.

13 Nov 2009

Researchers find a new way to tackle colon cancer

One difficulty with fighting cancer cells is that they are similar in many respects to the body's stem cells. By focusing on the differences, researchers at Karolinska Institutet have found a new way of tackling colon cancer. The study is presented in the prestigious journal Cell.

13 Nov 2009

New technology may lessen health and environmental concerns about nanotechnology industry

In an advance that could help ease health and environmental concerns about the emerging nanotechnology industry, scientists are reporting development of technology for changing the behavior of nanoparticles in municipal sewage treatment plants - their main gateway into the environment. Their study will be published online November 12 in ACS' journal Environmental Science & Technology.

13 Nov 2009

Scientists describe how HIV assemble at the membrane of infected cells and are released to attack healthy cells

Although recent advances have raised hopes that a protective vaccine can be developed, acquired immunodeficiency syndrome (AIDS) remains a major public health problem. Much has been learned about HIV-1, the virus that causes the disease.

13 Nov 2009

Lipid that accumulates in brain cells drives cell death, says research

The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators.

13 Nov 2009

Scientists to develop a treatment for rare genetic disorder, FOP

An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP), in which the body's skeletal muscles and soft connective tissue turns to bone, immobilizing patients over a lifetime with a second skeleton.

13 Nov 2009

New gene therapy may breach the armor of cancerous tumors

The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Researchers at the Cornell University College of Veterinary Medicine have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- a gene mutated in the majority of human cancers.

13 Nov 2009

New findings on human genome may be useful for developing specific AIDS drugs

The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.

13 Nov 2009

CMS approves FDG PET for initial staging of cervical cancer

SNM applauds the Centers for Medicare & Medicaid Services- (CMS) decision to expand coverage of FDG PET for the initial staging of cervical cancer without previously imposed restrictions.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Varian and SSI sign reseller's agreement

Varian, Inc. announced today that Steady State Imaging (SSI) has signed a reseller's agreement with Varian, Inc. regarding SSI's new SWIFT Software for Varian's research MRI Systems. SWIFT is a novel MRI technology that advances existing MR techniques with the ability to silently image structures and tissues previously invisible to conventional MRI systems.

13 Nov 2009

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Senesco Technologies, Inc. announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference.

12 Nov 2009

Transplantation of human mononuclear cells exerts a deleterious effect in rats with liver cirrhosis

The use of stem cells in regenerative medicine is not always beneficial for human health, it may even be harmful according to a work done by the universities of Granada and León. Scientists have demonstrated that transplantation of human mononuclear cells isolated from umbilical cord blood exerted a deleterious effect in rats with liver cirrhosis.

12 Nov 2009

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.

12 Nov 2009

New Cat B 750 FAST imaging agent launched by VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.

12 Nov 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.

12 Nov 2009

Cell News and Research

PAF receives additional funding support for serving patients with multiple myeloma

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

Findings on the use of Traumeel S in children with mucositis undergoing SCT presented

New knowledge of basic science may be applied in future medical treatments

Researchers find a new way to tackle colon cancer

New technology may lessen health and environmental concerns about nanotechnology industry

Scientists describe how HIV assemble at the membrane of infected cells and are released to attack healthy cells

Lipid that accumulates in brain cells drives cell death, says research

Scientists to develop a treatment for rare genetic disorder, FOP

New gene therapy may breach the armor of cancerous tumors

New findings on human genome may be useful for developing specific AIDS drugs

CMS approves FDG PET for initial staging of cervical cancer

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Varian and SSI sign reseller's agreement

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Transplantation of human mononuclear cells exerts a deleterious effect in rats with liver cirrhosis

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

New Cat B 750 FAST imaging agent launched by VisEn Medical

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News